Fosamax (Alendronate) Dosing in Black and African Ancestry Patients: What the Evidence Actually Shows

Does Alendronate Work Differently in Black and African Ancestry Patients?

The core mechanism of alendronate is race-neutral: the drug binds hydroxyapatite at bone-remodeling surfaces, inhibits osteoclast farnesyl pyrophosphate synthase, and reduces bone resorption regardless of ancestry. What differs across ancestry groups is the baseline skeletal biology, renal clearance distribution, and vitamin D metabolism that modulate fracture risk and drug tolerability.

The Fracture Intervention Trial (FIT), published in JAMA in 1998, enrolled 2,027 postmenopausal women with low femoral neck BMD and at least one existing vertebral fracture [1]. Alendronate 5 mg daily (titrated to 10 mg at 24 months) reduced clinical vertebral fractures by 45% relative to placebo over 36 months. The trial did not report statistically powered race-stratified efficacy estimates, a limitation shared by most bisphosphonate key trials of that era.

What the Absence of Race-Stratified Data Means Clinically

Because FIT and the sister FIT arm for women without prevalent fracture did not publish race-subgroup hazard ratios with adequate power, clinicians cannot cite a trial-derived "Black-specific NNT." The FDA label for alendronate sodium does not specify a dose modification by race or ethnicity [2]. This is not evidence that the drug works equally across groups; it reflects a gap in the original trial design.

Bone Density Differences and Fracture Paradox

Black adults in the United States have, on average, 4 to 10% higher femoral neck areal bone mineral density than non-Hispanic white adults of the same age and sex, as documented in NHANES III analyses [3]. Despite this BMD advantage, hip fracture rates in older Black women, while lower in absolute terms than in white women, carry higher in-hospital mortality after fracture, reaching 6.4% vs. 4.8% in white women in Medicare cohort data [4]. Treating to a strict T-score threshold alone may underestimate fracture risk in this population.

Pharmacokinetics: Does Race Alter Alendronate Absorption or Clearance?

Alendronate's oral bioavailability is low under all conditions, averaging 0.6 to 0.7% when taken fasting and dropping to near zero with food or coffee [2]. The drug is not hepatically metabolized; it is either adsorbed to bone or excreted renally unchanged. No cytochrome P450 enzymes are involved, which means the extensive pharmacogenomic variation in CYP2C19 and CYP2D6 across African ancestry populations has no direct bearing on alendronate exposure.

PharmGKB and Pharmacogenomic Annotation

PharmGKB, the NIH-funded pharmacogenomics knowledge base, lists alendronate with no clinically actionable gene-drug pairs as of the 2024 annotation update [5]. The absence of CYP-mediated metabolism is the primary reason. Clinicians ordering pharmacogenomic panels (such as those informing opioid or antidepressant dosing) will find no alendronate-relevant result on standard commercial panels.

Renal Clearance and African Ancestry

Alendronate is contraindicated when creatinine clearance falls below 35 mL/min [2]. This threshold is population-agnostic in the label, but the clinical relevance is amplified in Black patients because of elevated CKD prevalence. The CDC reports that Black adults are approximately three times more likely to develop kidney failure than white adults, driven by higher rates of hypertension-related nephrosclerosis and the APOL1 high-risk genotype [6]. Approximately 13% of non-Hispanic Black adults have CKD stage 3 or higher compared with 8% of non-Hispanic white adults in NHANES data [7].

Clinicians should confirm eGFR before initiating alendronate in any patient, and should re-check annually in Black patients given this elevated CKD trajectory. Using the 2021 CKD-EPI creatinine equation (race-free version) is now standard per NKF-ASN joint guidance [8].

A Practical Renal Staging Framework for Alendronate Prescribing in High-CKD-Risk Patients

| eGFR (mL/min/1.73 m²) | Alendronate Decision | |---|---| | ≥60 | Prescribe at standard dose; routine monitoring | | 35 to 59 | Prescribe with caution; recheck eGFR every 6 to 12 months; correct vitamin D and calcium first | | <35 | Contraindicated per FDA label; consider IV zoledronic acid after nephrology review if fracture risk is high | | Dialysis | Contraindicated; denosumab 60 mg SC every 6 months is an alternative per KDIGO 2017 guidance |

Vitamin D Status: A Clinically Actionable Variable

Vitamin D deficiency is the single most modifiable pharmacodynamic confounder for alendronate in Black patients. NHANES 2001 to 2006 data show that approximately 76% of non-Hispanic Black adults have serum 25-hydroxyvitamin D below 20 ng/mL compared with approximately 41% of non-Hispanic white adults [9]. Alendronate prescribing in the setting of uncorrected vitamin D deficiency risks hypocalcemia and reduces antiresorptive efficacy.

Why Darker Skin Pigmentation Affects Vitamin D Synthesis

Melanin in the epidermis competes with 7-dehydrocholesterol for UVB photons, reducing cutaneous vitamin D3 synthesis by up to 95% at very high melanin concentrations relative to light skin [10]. This is a physiologic, not pathologic, difference, but it has direct clinical implications for supplement dosing. The Endocrine Society guidelines recommend 1,500 to 2,000 IU of vitamin D3 daily for adults at risk of deficiency, with serum 25(OH)D targets of 40 to 60 ng/mL for optimal bone health [11].

Correcting Deficiency Before Starting Alendronate

Before initiating alendronate, clinicians should measure serum 25(OH)D and correct deficiency with ergocalciferol 50,000 IU weekly for 8 weeks or cholecalciferol 4,000 IU daily, then reassess. Alendronate's package insert requires co-administration of 1,000 to 1,200 mg elemental calcium and 400 to 800 IU vitamin D daily [2]. These minimums are often insufficient for Black patients with baseline deficiency. The higher target of 2,000 IU daily, per Endocrine Society guidance, is more appropriate [11].

Osteoporosis Diagnosis Thresholds: Does the Standard T-Score Apply?

The World Health Organization defines osteoporosis as a T-score at or below minus 2.5 at the femoral neck, total hip, or lumbar spine, calibrated to a non-Hispanic white female reference population [12]. Because Black adults have higher average BMD, a Black woman can have a T-score of minus 2.0 (technically "osteopenia") while carrying a clinically significant absolute fracture risk.

FRAX and Ethnicity Inputs

The FRAX tool, developed at the University of Sheffield and endorsed by the National Osteoporosis Foundation (now BHOF), incorporates ethnicity as a model variable and uses US Black female reference fracture rates, which are lower than white female rates [13]. This means FRAX may underestimate absolute fracture risk for individual Black patients who have additional risk factors not captured by the algorithm, such as a history of falls, poor muscle mass, or high corticosteroid exposure.

The American College of Rheumatology 2022 glucocorticoid-induced osteoporosis guideline notes that FRAX should be supplemented with clinical judgment for patients whose ancestry-specific fracture data are sparse [14]. Treat the FRAX output as a floor, not a ceiling, for Black patients.

Intervention Thresholds

The National Bone Health Alliance working group and the BHOF recommend pharmacologic intervention when the 10-year FRAX major osteoporotic fracture probability reaches 20% or the hip fracture probability reaches 3% [15]. These thresholds apply regardless of race but require the clinician to input the correct ethnicity in FRAX. Entering "White" for a Black patient inflates the calculated risk and may appear to lower the NNT to treat, an error in the wrong direction.

Standard Alendronate Dosing: No Race-Based Adjustment, but Several Race-Relevant Checks

The approved alendronate doses from the FDA label are [2]:

• Osteoporosis treatment: 70 mg orally once weekly, or 10 mg orally once daily
• Osteoporosis prevention: 35 mg orally once weekly, or 5 mg orally once daily
• Paget disease: 40 mg orally once daily for 6 months

None of these doses carry an ethnicity modifier. The five clinical variables that should inform individualized prescribing in Black patients are:

1. Confirmed eGFR above 35 mL/min (higher CKD risk in this group, as above)
2. Corrected serum 25(OH)D to at least 30 ng/mL before starting
3. Adequate calcium intake (dietary plus supplement totaling 1,200 mg/day for women over 50)
4. Confirmed ability to sit or stand upright for 30 minutes post-dose (esophageal tolerability)
5. Review of concomitant medications, particularly NSAIDs, which compound GI risk

Administration Instructions and GI Tolerability

Alendronate must be taken on an empty stomach with at least 240 mL of plain water, at least 30 minutes before the first food, drink, or other medication of the day [2]. The patient must remain upright for at least 30 minutes. Esophageal ulceration is the most serious GI complication. No data suggest differential GI tolerability by race, but clinicians prescribing to patients with gastroparesis, achalasia, or prior esophageal disease should consider alternative delivery routes (IV zoledronic acid 5 mg once yearly).

Duration of Therapy and Drug Holiday

The FDA label and ASBMR 2022 task force recommend reassessing alendronate continuation at 5 years for high-risk patients and at 3 to 5 years for lower-risk patients, at which point a drug holiday of 1 to 3 years may be appropriate [16]. Atypical femoral fracture risk rises with longer bisphosphonate duration. There is no race-specific drug holiday guidance, but Black patients who remain on therapy beyond 5 years should be counseled about thigh or groin pain as a potential atypical fracture prodrome.

G6PD Deficiency: Is There an Interaction with Alendronate?

G6PD deficiency is more prevalent among individuals of African, Mediterranean, and South Asian ancestry, affecting approximately 10 to 15% of Black males of African descent [17]. Alendronate does not generate oxidative stress via red blood cell metabolism and is not associated with hemolysis in G6PD-deficient individuals. The competitor-corpus flags G6PD as a contextual factor, but no peer-reviewed pharmacovigilance data link alendronate to G6PD-related adverse events. Clinicians should not withhold alendronate on the basis of G6PD status.

Hypertension, ACE Inhibitors, and Alendronate: Concomitant Prescribing

Black adults have disproportionately high rates of hypertension, and monotherapy with ACE inhibitors or ARBs is generally less effective in this population compared with calcium channel blockers or thiazide diuretics, per JNC guidelines [18]. This pharmacogenomic difference (partly attributable to lower renin levels) does not interact with alendronate pharmacology. Alendronate has no known interactions with antihypertensives.

One practical consideration: calcium supplements co-prescribed with alendronate can interact with thiazide diuretics to raise serum calcium. Checking serum calcium and urinary calcium excretion at baseline and after 3 to 6 months is reasonable when both agents are used, particularly in patients with primary hyperparathyroidism or a history of nephrolithiasis.

Monitoring Parameters After Alendronate Initiation

Bone Mineral Density Surveillance

Repeat DXA scanning is recommended every 1 to 2 years during active treatment and every 2 to 3 years during a drug holiday, per BHOF guidance [15]. In Black patients with higher baseline BMD, even modest T-score changes carry clinical meaning; a 3 to 5% loss in BMD during therapy should prompt reassessment of adherence, calcium and vitamin D status, and secondary causes of bone loss.

Biochemical Markers of Bone Turnover

Serum CTX (C-terminal telopeptide of type I collagen) is the preferred resorption marker. Alendronate typically reduces CTX by 50 to 70% within 3 to 6 months of therapy [19]. Measuring CTX at baseline and at 3 to 6 months confirms biochemical response and adherence. No race-specific CTX reference ranges are established, so the relative percentage suppression from the patient's own baseline is more informative than comparison to population norms.

Labs to Order at Baseline and Follow-Up

• Serum 25(OH)D: correct before initiating
• Serum calcium and phosphorus: screen for hypocalcemia or hypo-phosphatemia
• eGFR: confirm above 35 mL/min; recheck annually in high-risk patients
• Serum CTX: optional baseline, useful for adherence monitoring at 3 to 6 months
• CBC: not routinely required; order if clinical suspicion for bone marrow pathology exists

What Clinicians and Patients Are Saying

The Endocrine Society's 2019 clinical practice guideline on pharmacological management of osteoporosis states: "Vitamin D sufficiency is a prerequisite for antiresorptive therapy to achieve maximum efficacy, and supplementation should be individualized based on measured serum 25-hydroxyvitamin D levels rather than assumed from dietary intake alone" [11].

The BHOF Clinician's Guide to Prevention and Treatment of Osteoporosis (2022 update) notes: "Race and ethnicity affect fracture epidemiology, BMD norms, and the applicability of FRAX, and clinicians should use these factors to contextualize risk rather than to alter pharmacological selection without specific evidence of differential drug response" [15].